These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34297770)

  • 1. Archival bone marrow smears are useful in targeted next-generation sequencing for diagnosing myeloid neoplasms.
    Sadato D; Hirama C; Kaiho-Soma A; Yamaguchi A; Kogure H; Takakuwa S; Ogawa M; Doki N; Ohashi K; Harada H; Oboki K; Harada Y
    PLoS One; 2021; 16(7):e0255257. PubMed ID: 34297770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of mutations in myeloid malignancies through paired-sample analysis of microdroplet-PCR deep sequencing data.
    Cheng DT; Cheng J; Mitchell TN; Syed A; Zehir A; Mensah NYT; Oultache A; Nafa K; Levine RL; Arcila ME; Berger MF; Hedvat CV
    J Mol Diagn; 2014 Sep; 16(5):504-518. PubMed ID: 25017477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing.
    Terui K; Toki T; Taga T; Iwamoto S; Miyamura T; Hasegawa D; Moritake H; Hama A; Nakashima K; Kanezaki R; Kudo K; Saito AM; Horibe K; Adachi S; Tomizawa D; Ito E
    Genes Chromosomes Cancer; 2020 Mar; 59(3):160-167. PubMed ID: 31606922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.
    Luthra R; Patel KP; Routbort MJ; Broaddus RR; Yau J; Simien C; Chen W; Hatfield DZ; Medeiros LJ; Singh RR
    J Mol Diagn; 2017 Mar; 19(2):255-264. PubMed ID: 28017569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
    Duncavage EJ; Tandon B
    Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
    Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
    [No Abstract]   [Full Text] [Related]  

  • 7. Archived bone marrow smears are an excellent source for NGS-based mutation detection in acute myeloid leukemia.
    Al Hinai ASA; Grob T; Kavelaars FG; Rijken M; Zeilemaker A; Erpelinck-Verschueren CAJ; Gussinklo KJ; Sanders MA; van Lom K; Valk PJM
    Leukemia; 2020 Aug; 34(8):2220-2224. PubMed ID: 32060404
    [No Abstract]   [Full Text] [Related]  

  • 8. Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers.
    Ramani NS; Chen H; Broaddus RR; Lazar AJ; Luthra R; Medeiros LJ; Patel KP; Rashid A; Routbort MJ; Stewart J; Tang Z; Bassett R; Manekia J; Barkoh BA; Dang H; Roy-Chowdhuri S
    Cancer Cytopathol; 2021 May; 129(5):374-382. PubMed ID: 33119213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA.
    Supplee JG; Milan MSD; Lim LP; Potts KT; Sholl LM; Oxnard GR; Paweletz CP
    Lung Cancer; 2019 Aug; 134():96-99. PubMed ID: 31320002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Next-Generation Sequencing Pipeline Outperforms a Combined Approach Using Sanger Sequencing and Multiplex Ligation-Dependent Probe Amplification in Targeted Gene Panel Analysis.
    Schenkel LC; Kerkhof J; Stuart A; Reilly J; Eng B; Woodside C; Levstik A; Howlett CJ; Rupar AC; Knoll JHM; Ainsworth P; Waye JS; Sadikovic B
    J Mol Diagn; 2016 Sep; 18(5):657-667. PubMed ID: 27376475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seven Co-Occurring Mutations in a Patient with Acute Myeloid Leukemia Identified by Next-Generation Sequencing.
    Lee JH; Lee JH
    Clin Lab; 2019 Jun; 65(6):. PubMed ID: 31232041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules.
    Ye W; Hannigan B; Zalles S; Mehrotra M; Barkoh BA; Williams MD; Cabanillas ME; Edeiken-Monroe B; Hu P; Duose D; Wistuba II; Medeiros LJ; Stewart J; Luthra R; Roy-Chowdhuri S
    Cancer Cytopathol; 2019 Mar; 127(3):146-160. PubMed ID: 30620446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer.
    Janku F; Zhang S; Waters J; Liu L; Huang HJ; Subbiah V; Hong DS; Karp DD; Fu S; Cai X; Ramzanali NM; Madwani K; Cabrilo G; Andrews DL; Zhao Y; Javle M; Kopetz ES; Luthra R; Kim HJ; Gnerre S; Satya RV; Chuang HY; Kruglyak KM; Toung J; Zhao C; Shen R; Heymach JV; Meric-Bernstam F; Mills GB; Fan JB; Salathia NS
    Clin Cancer Res; 2017 Sep; 23(18):5648-5656. PubMed ID: 28536309
    [No Abstract]   [Full Text] [Related]  

  • 14. Sanger Confirmation Is Required to Achieve Optimal Sensitivity and Specificity in Next-Generation Sequencing Panel Testing.
    Mu W; Lu HM; Chen J; Li S; Elliott AM
    J Mol Diagn; 2016 Nov; 18(6):923-932. PubMed ID: 27720647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Next-Generation Sequencing of Circulating Tumor DNA, Bone Marrow, and Peripheral Blood Mononuclear Cells in Pediatric AML.
    Ruan M; Liu L; Qi B; Chen X; Chang L; Zhang A; Liu F; Wang S; Liu X; Chen X; Zhang L; Guo Y; Zou Y; Zhang Y; Chen Y; Liu L; Cao S; Lou F; Wang C; Zhu X
    Front Oncol; 2021; 11():666470. PubMed ID: 34422630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation sequencing in residual liquid-based cytology specimens for cancer genome analysis.
    Yamaguchi T; Akahane T; Harada O; Kato Y; Aimono E; Takei H; Tasaki T; Noguchi H; Nishihara H; Kamata H; Tanimoto A
    Diagn Cytopathol; 2020 Nov; 48(11):965-971. PubMed ID: 32511899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of copy number variant detection from panel-based next-generation sequencing data.
    Yao R; Yu T; Qing Y; Wang J; Shen Y
    Mol Genet Genomic Med; 2019 Jan; 7(1):e00513. PubMed ID: 30565893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia.
    Short NJ; Patel KP; Albitar M; Franquiz M; Luthra R; Kanagal-Shamanna R; Wang F; Assi R; Montalban-Bravo G; Matthews J; Ma W; Loghavi S; Takahashi K; Issa GC; Kornblau SM; Jabbour E; Garcia-Manero G; Kantarjian HM; Estrov Z; Ravandi F
    Blood Adv; 2020 Apr; 4(8):1670-1677. PubMed ID: 32324887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variant allele frequencies do not correlate well with myeloblast counts in a clinically validated gene sequencing panel for routine acute myeloid leukemia workup.
    Toth LN; Green D; Peterson J; Deharvengt SJ; de Abreu FB; Loo EY
    Leuk Lymphoma; 2019 Oct; 60(10):2415-2422. PubMed ID: 30997856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design.
    Aguilera-Diaz A; Vazquez I; Ariceta B; Mañú A; Blasco-Iturri Z; Palomino-Echeverría S; Larrayoz MJ; García-Sanz R; Prieto-Conde MI; Del Carmen Chillón M; Alfonso-Pierola A; Prosper F; Fernandez-Mercado M; Calasanz MJ
    PLoS One; 2020; 15(1):e0227986. PubMed ID: 31978184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.